*FDA panel says suvorexant safe, effective at lower doses. On Monday, the FDA's internal reviewers published a report expressing concern about suvorexant's potential to cause next-day sleepiness and impaired driving.» Read More
Bristol-Myers Squibb said it will pay up to $1 million to settle a criminal probe of a failed deal that would have delayed generic sales of blockbuster drug Plavix.
Shares of Amgen and Johnson & Johnson traded lower after a U.S. advisory panel called for marketing restrictions on the companies' popular anemia drugs.
We got an email today about guest blogger Jeff Mishlove's last stock picks--and Jeff feels he wants to address the issues raised by the emailer--that perhaps other contestants have as well. A reminder that Jeff gets no compensation for his blog posts. Here he is: A contest participant has recently raised several concerns, due to the fact that the recommendations I posted on Tuesday have done so poorly – while, simultaneously, I myself was on the leaderboard and have also benefited from sales of my Handbook for Contestants. The implicit suggestion was that, perhaps, I deliberately posted lousy stock picks at the end of this event – in order to confuse the competition and gain an edge for myself.
Analyst actions and earnings updates were some of the catalysts behind the most actively traded stocks on Thursday.
The maker of the powerful painkiller OxyContin and three of its current and former executives pleaded guilty to misleading the public about the drug's risk of addiction, a federal prosecutor and the company said.
While I'm watching the webcast of the FDA Advisory Committee Meeting on the anemia drugs (Amgen, Johnson & Johnson), I wanted to hop on my TV versus print soapbox one more time.As I posted yesterday, I had asked a Dendreon spokeswoman for an interview with CEO Dr. Mitchell Gold in the wake of the FDA sending the company an "approvable letter" for its prostate cancer treatment Provenge.
The New England Journal of Medicine said in an editorial Wednesday that Merck's Gardasil, a treatment for human papillomavirus or HPV, appears to be safe and effective but "a cautious approach may be warranted" due to unanswered questions about the drug's long-term effectiveness and potential for adverse effects that could emerge over time.
Analyst upgrades and earnings reports were some of the catalysts behind the most actively traded stocks on Wednesday.
As I write this, Dendreon is about to cross the 100,000,000 trading volume threshold. If Cisco hadn't made news as well, DNDN would easily be the most active stock on any of the major exchanges today. Yesterday the FDA sent Dendreon what's called an "approvable letter". I've called it a euphemism for "delay", but essentially it means the agency says it might eventually approve a product if or when the company provides whatever other information it wants.
Bristol-Myers Squibb and Isis Pharmaceuticals, Inc have announced a collaboration to discover, develop and commercialize new drugs for the prevention and treatment of cardiovascular disease.
The top 4 celebrities remain constant with Jonathan Tucker holding onto his lead with only $62,581.29 separating him from Stephen Collins. Poker champion Moneymaker is betting on Allscripts Healthcare to move him up from 4th on strong earnings after the bell Tuesday. And Hall of Famer Johnny Bench is counting on American Oriental Bioengineering to continue to perform--as he's in 5th place.
Hey folks. Jeff Mishlove is here with his picks today. Let's get right to his post: This has been a very busy time for me, so I am submitting this blog a bit later than usual. However, the lateness allows me to see that the picks I recommended for yesterday are doing quite well. Two of the five are among the top two eligible stocks for the contest on Tuesday. Those are aQuantive and Blue Nile – up, as I am writing, 11.98% and 17.21% respectively.
U.S. Food and Drug Administration staffers on Tuesday expressed continued caution over the use of anemia drugs sold by Amgen and Johnson & Johnson , according to an agency document released on Tuesday.
Fox tells us it's developing a sequel to "Wall Street," and published reports say Michael Douglas will reprise his role as the villainous Gordon Gekko. The first movie didn't do that well at the box office back in 1987 ($48 million worldwide), but the REAL Wall Street loved it. Traders still quote dialogue: "If you need a friend, get a dog."
Hey everyone, here's Jeff Mishlove with his latest round of contest stock picks. He seems to be doing pretty well with his picks. Are you? Here he is: As I reported in Friday’s blog, and earlier, Week 8 of the contest was a thrilling experience for me – as I ended up on the weekly leaderboard in second place – with a portfolio that appreciated 112.98% for the week.
Celgene said quarterly earnings more than tripled but sales of its most important product, cancer drug Revlimid, were smaller than expected and its shares fell nearly 7% in premarket trading.
French drugmaker Sanofi-Aventis on Thursday reported declining first-quarter profits, citing adverse currency movements, generic competition and a strong quarter in 2006.
A new study offers the millions of people who have osteoporosis the hope of taking a drug to treat it only once a year. The New England Journal of Medicine reports that patients who got a once-a-year infusion of the Novartis drug Reclast saw a 70% reduction in the risk of spinal fractures and a 40% drop in the risk of hip fractures.
GlaxoSmithKline's Alli (pronounced "ally" -- don't ask me why they put an "i" at the end) is the new over-the-counter version of prescription Xenical from Roche. It's a diet pill, but as I previously blogged, it has potentially embarrassing side effects. On the plus side, GSK says you can subtract 50% more pounds if you use Alli as directed. But, if you still eat too many fatty foods, you could run into trouble.
Here's our latest contest "stock report." Dow Jones certainly proved a big winner with the unsolicited takeover bid by Rupert Murdoch. But DJ wasn't the only stock benefiting from M&A talk--as you can see. Meanwhile, earnings took their toll on the worst performers. There's a couple of new names (MOVE, ENTG) on the most active list--while the widely helds remained the same.